Support Alert

Class 4 Medicines Defect Information: Rifadin (rifampicin) 150mg Capsules (MDR 127-09/19)

Aventis Pharma Limited t/a Sanofi has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that a change to the Patient Information Leaflet, concerning possible side effects for Rifadin (rifampicin) 150mg Capsules, has not been implemented by the required timeline.

Loading...
Photo of a happy pharmacist saving money on her RPS membership

Join today with an Annual Direct Debit

Become an RPS Member today and save up to £26 by choosing annual Direct Debit
OR spread the cost by switching to monthly payments.

RPS membership is better value than ever in 2024 - join today!

BECOME A MEMBER TODAY